![](/img/cover-not-exists.png)
L21An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID):
Fumagalli, E., Reichardt, P., Kang, Y., Blay, J., Joensuu, H., Schaefer, K.B., Kuss, I., Kappeler, C., Demetri, G.D.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv344.21
Date:
October, 2015
File:
PDF, 35 KB
english, 2015